BridgeBio Pharma, Inc. (BBIO) shareholders
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.30+0.13 (+0.17%)
Close on Nov 13, 2026Market cap $15.25BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
99.4%
194M of 195M shares
Institutional holders
474
86 new, 68 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
0 buys · 140 sales
Net sold $94.64M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Viking Global Investors LP Joint filing with Halvorsen Ole Andreas (11.70%), Ott David C. (11.70%) and 5 more | 22,055,375 | 11.70% | 13D (active) amendment | Jan 31, 2025 |
| KKR & Co. Inc. Joint filing with George R. Roberts (10.10%), Henry R. Kravis (10.10%) and 6 more | 19,260,971 | 10.10% | 13D (active) amendment | Mar 5, 2025 |
| Ott David C. Joint filing with Halvorsen Ole Andreas (9.80%), Shabet Rose Sharon (9.80%) and 5 more | 18,602,920 | 9.80% | 13D (active) amendment | Jun 27, 2025 |
| Halvorsen Ole Andreas Joint filing with Ott David C. (8.20%), Shabet Rose Sharon (8.20%) and 5 more | 15,893,934 | 8.20% | 13D (active) amendment | Nov 14, 2025 |
| George R. Roberts Joint filing with Henry R. Kravis (7.00%), KKR & Co. Inc. (7.00%) and 6 more | 13,260,971 | 7.00% | 13D (active) amendment | May 12, 2025 |
| Janus Henderson Group PLC | 13,179,013 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| Shabet Rose Sharon Joint filing with Halvorsen Ole Andreas (6.80%), Ott David C. (6.80%) and 5 more | 13,026,367 | 6.80% | 13D (active) amendment | Feb 12, 2026 |
| Husen, Avner A. Joint filing with Dapice Joshua J. (5.50%), Dreyfuss, Philip D. (5.50%) and 13 more | 10,743,063 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| Short Daniel S. Joint filing with Wehrly, Mark C. (5.20%), Dreyfuss, Philip D. (5.20%) and 13 more | 10,226,063 | 5.20% | 13G (passive) | May 22, 2026 |
| BlackRock, Inc. | 9,892,226 | 5.10% | 13G (passive) | Sep 30, 2026 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP Joint filing with Halvorsen Ole Andreas (5.00%), Shabet Rose Sharon (5.00%) and 4 more | 9,792,219 | 5.00% | 13D (active) amendment | Jul 9, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 14,110,278 | 7.24% | $1.05B | New | 0.43% |
| Kohlberg Kravis Roberts & Co. L.P. | 13,260,971 | 6.81% | $987.68M | – | 17.30% |
| Farallon Capital Management LLC | 10,743,063 | 5.51% | $800.14M | +1,377,600 | 3.69% |
| BlackRock, Inc. | 10,287,156 | 5.28% | $766.19M | −3,920,601 | 0.01% |
| Viking Global Investors LP | 9,949,219 | 5.11% | $741.02M | −1,893,215 | 2.11% |
| Vanguard Capital Management LLC | 7,898,973 | 4.05% | $588.32M | +139,478 | 0.01% |
| Vanguard Portfolio Management LLC | 7,656,722 | 3.93% | $570.27M | −423,851 | 0.03% |
| Wellington Management Group Llp | 5,308,924 | 2.73% | $395.41M | +2,824,971 | 0.07% |
| Two Sigma Investments, LP | 4,722,185 | 2.42% | $351.71M | +1,601,554 | 0.25% |
| Aisling Capital Management LP | 4,589,611 | 2.36% | $341.83M | −500,000 | 72.48% |
| State Street Corp | 4,435,932 | 2.28% | $330.39M | −498,388 | 0.01% |
| Citadel Advisors LLC | 3,760,028 | 1.93% | $280.05M | +586,088 | 0.03% |
| Invesco Ltd. | 3,700,934 | 1.90% | $275.65M | −891,880 | 0.02% |
| D. E. Shaw & Co., Inc. | 3,633,007 | 1.86% | $270.59M | +1,087,521 | 0.13% |
| Geode Capital Management, LLC | 3,418,419 | 1.75% | $254.67M | −1,499,611 | 0.01% |
| Jane Street Group, LLC | 2,934,193 | 1.51% | $218.54M | +1,176,521 | 0.02% |
| JPMorgan Chase & Co | 2,397,995 | 1.23% | $173.23M | +1,085,736 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 2,252,000 | 1.16% | $167.73M | +1,653,000 | 0.24% |
| Franklin Resources Inc | 2,160,173 | 1.11% | $160.89M | −278,752 | 0.03% |
| Polar Capital Holdings Plc | 2,063,609 | 1.06% | $153.70M | −455,697 | 0.36% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 474 | 194M | 99.4% | 86 / 172 | 167 / 68 | 42M | 29M |
| Q1 2026 | 461 | 195M | 99.9% | 91 / 182 | 135 / 56 | 38M | 18M |
| Q4 2025 | 434 | 191M | 98.1% | 102 / 155 | 138 / 51 | 25M | 19M |
| Q3 2025 | 392 | 185M | 95.2% | 75 / 148 | 134 / 38 | 17M | 21M |
| Q2 2025 | 359 | 189M | 97.0% | 92 / 136 | 105 / 34 | 28M | 26M |
| Q1 2025 | 304 | 187M | 95.7% | 74 / 119 | 80 / 29 | 30M | 20M |
| Q4 2024 | 263 | 177M | 90.7% | 49 / 103 | 81 / 36 | 16M | 13M |
| Q3 2024 | 254 | 174M | 89.3% | 40 / 105 | 75 / 34 | 29M | 17M |
| Q2 2024 | 251 | 175M | 89.9% | 45 / 106 | 74 / 36 | 18M | 20M |
| Q1 2024 | 244 | 177M | 91.0% | 42 / 100 | 80 / 44 | 15M | 8M |
| Q4 2023 | 247 | 171M | 87.6% | 53 / 89 | 77 / 26 | 19M | 11M |
| Q3 2023 | 221 | 162M | 83.1% | 54 / 66 | 75 / 27 | 25M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
449 funds held BBIO in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,600,403 | 2.87% | $417.12M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 4,039,952 | 2.07% | $300.90M | 0.16% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,162,851 | 1.62% | $253.31M | 0.66% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,330,329 | 1.20% | $173.56M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,974,544 | 1.01% | $147.06M | 0.15% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund | 1,909,659 | 0.98% | $142.23M | 0.64% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,724,983 | 0.89% | $138.15M | 0.62% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 1,590,382 | 0.82% | $118.45M | 2.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,477,181 | 0.76% | $110.02M | 1.02% | Jun 30, 2026 |
| Invesco Discovery Fund | 1,315,232 | 0.68% | $87.15M | 1.11% | May 31, 2026 |
| iShares Biotechnology ETF | 1,198,062 | 0.62% | $89.23M | 0.98% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund | 1,150,147 | 0.59% | $85.66M | 0.65% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 1,125,373 | 0.58% | $74.57M | 1.35% | May 29, 2026 |
| iShares Russell Mid-Cap Growth ETF | 940,494 | 0.48% | $70.05M | 0.32% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 871,645 | 0.45% | $57.76M | 0.14% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neil Kumar | Chief Executive Officer, Director | 5,058,739 | 2.60% | Sep 21, 2026 |
| Maricel Apuli | Chief Accounting Officer | 120,687 | 0.06% | Nov 3, 2026 |
| Thomas Trimarchi | President and CFO | 336,529 | 0.17% | Aug 18, 2026 |
| Brian C. Stephenson | CFO and Treasurer | 110,964 | 0.06% | Feb 27, 2025 |
| Andrea Ellis | Director | 39,746 | 0.02% | Jul 13, 2026 |
| Jennifer E. Cook | Director | 8,383 | 0.00% | Jul 13, 2026 |
| Ronald J. Daniels | Director | 20,981 | 0.01% | Jun 24, 2026 |
| Andrew Lo | Director | 68,662 | 0.04% | Jun 24, 2026 |
| Charles J. Homcy | Director | 919,876 | 0.47% | Jun 24, 2026 |
| Fred Hassan | Director | 29,879 | 0.02% | Jun 24, 2026 |
| Frank McCormick | Director | 767,244 | 0.39% | Jun 24, 2026 |
| James C. Momtazee | Director | 99,070 | 0.05% | Jun 24, 2026 |
| Eric Aguiar | Director | 10,579 | 0.01% | Jun 24, 2026 |
| Hannah Valantine | Director | 9,657 | 0.00% | Jun 24, 2026 |
| Douglas A. Dachille | Director | 30,579 | 0.02% | Jun 24, 2026 |
| Ali J. Satvat | Director | 169,983 | 0.09% | Jun 24, 2026 |
| Randal W. Scott | Director | 19,389 | 0.01% | May 19, 2026 |
| Global Opportunities Illiquid Investments Sub-Master LP Viking | 10% owner | 22,055,375 | 11.32% | Jul 1, 2025 |
| Rose Sharon Shabet | 10% owner | 11,736,137 | 6.02% | Jul 1, 2025 |
| Global Opportunities Parent GP LLC Viking | 10% owner | – | – | Jul 1, 2025 |
| Global Investors Lp Viking | 10% owner | – | – | Jul 1, 2025 |
| Ole Andreas Halvorsen | 10% owner | 18,555,375 | 9.53% | Jul 1, 2025 |
| David C. Ott | 10% owner | – | – | Jul 1, 2025 |
| Global Opportunities GP LLC Viking | 10% owner | 25,120,991 | 12.90% | Jul 1, 2025 |
| Global Opportunities Portfolio GP LLC Viking | 10% owner | – | – | Jul 1, 2025 |
| Group Co. Inc. KKR | 10% owner | – | – | May 14, 2025 |
| George R. Roberts | 10% owner | – | – | May 14, 2025 |
| Henry R. Kravis | 10% owner | 13,260,971 | 6.81% | May 14, 2025 |
| Group Partnership L.P. KKR | 10% owner | 36,900,661 | 18.94% | May 14, 2025 |
| & Co. Inc. KKR | 10% owner | 25,260,971 | 12.97% | May 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Maricel Apuli Chief Accounting Officer | Oct 30, 2026 | Sale(10b5-1 plan) | −2,000 | $72.85 | $145.70K | 120,687 |
| Neil Kumar Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −8,721 | $69.01 | $601.84K | 496,965 |
| Neil Kumar Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −1,279 | $69.57 | $88.98K | 495,686 |
| Neil Kumar Chief Executive Officer, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −8,100 | $83.86 | $679.27K | 507,586 |
| Neil Kumar Chief Executive Officer, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −1,800 | $84.69 | $152.44K | 505,786 |
| Neil Kumar Chief Executive Officer, Director | Aug 19, 2026 | Sale(10b5-1 plan) | −100 | $85.65 | $8.57K | 505,686 |
| Neil Kumar Chief Executive Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −1,199 | $83.77 | $100.44K | 243,327 |
| Neil Kumar Chief Executive Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −17,279 | $82.21 | $1.42M | 259,128 |
| Neil Kumar Chief Executive Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −1,900 | $81.15 | $154.19K | 276,407 |
| Neil Kumar Chief Executive Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −14,602 | $82.99 | $1.21M | 244,526 |
| Neil Kumar Chief Executive Officer, Director | Aug 16, 2026 | Option exercise | +11,554 | – | – | 308,024 |
| Neil Kumar Chief Executive Officer, Director | Aug 16, 2026 | Option exercise | +33,544 | – | – | 276,871 |
| Neil Kumar Chief Executive Officer, Director | Aug 16, 2026 | Option exercise | +19,599 | – | – | 296,470 |
| Neil Kumar Chief Executive Officer, Director | Aug 16, 2026 | Option exercise | +6,520 | – | – | 314,544 |
| Neil Kumar Chief Executive Officer, Director | Aug 16, 2026 | Tax withholding | −36,237 | $79.86 | $2.89M | 278,307 |
| Thomas Trimarchi President and CFO | Aug 16, 2026 | Tax withholding | −22,781 | $79.86 | $1.82M | 336,529 |
| Maricel Apuli Chief Accounting Officer | Aug 16, 2026 | Tax withholding | −4,714 | $79.86 | $376.46K | 122,687 |
| Maricel Apuli Chief Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −2,000 | $80.06 | $160.12K | 127,401 |
| Jennifer E. Cook Director | Jul 9, 2026 | Sale(10b5-1 plan) | −112,422 | $90.00 | $10.12M | 8,383 |
| Jennifer E. Cook Director | Jul 9, 2026 | Option exercise | +19,000 | $8.45 | $160.55K | 27,383 |
| Jennifer E. Cook Director | Jul 9, 2026 | Option exercise | +112,422 | $29.00 | $3.26M | 139,805 |
| Jennifer E. Cook Director | Jul 9, 2026 | Option exercise | +17,167 | $16.75 | $287.55K | 156,972 |
| Jennifer E. Cook Director | Jul 9, 2026 | Sale(10b5-1 plan) | −36,167 | $84.00 | $3.04M | 120,805 |
| Andrea Ellis Director | Jul 9, 2026 | Option exercise | +17,167 | $16.75 | $287.55K | 39,746 |
| Andrea Ellis Director | Jul 9, 2026 | Sale(10b5-1 plan) | −17,167 | $84.00 | $1.44M | 22,579 |
| Jennifer E. Cook Director | Jun 24, 2026 | Option exercise | +20,000 | $8.45 | $169.00K | 28,383 |
| Jennifer E. Cook Director | Jun 24, 2026 | Option exercise | +17,167 | $16.75 | $287.55K | 45,550 |
| Jennifer E. Cook Director | Jun 24, 2026 | Sale(10b5-1 plan) | −37,167 | $70.00 | $2.60M | 8,383 |
| Hannah Valantine Director | Jun 23, 2026 | Sale(10b5-1 plan) | −2,196 | $68.57 | $150.58K | 9,259 |
| Jennifer E. Cook Director | Jun 23, 2026 | Sale(10b5-1 plan) | −2,196 | $68.57 | $150.58K | 8,383 |
| Ali J. Satvat Director | Jun 22, 2026 | Award | +3,990 | – | – | 169,983 |
| Andrew Lo Director | Jun 22, 2026 | Award | +3,990 | – | – | 18,079 |
| Douglas A. Dachille Director | Jun 22, 2026 | Award | +3,990 | – | – | 10,579 |
| Hannah Valantine Director | Jun 22, 2026 | Sale(10b5-1 plan) | −2,808 | $68.00 | $190.94K | 11,455 |
| Hannah Valantine Director | Jun 22, 2026 | Option exercise | +2,808 | $41.73 | $117.18K | 14,263 |
| Hannah Valantine Director | Jun 22, 2026 | Award | +3,990 | – | – | 11,455 |
| Eric Aguiar Director | Jun 22, 2026 | Award | +3,990 | – | – | 10,579 |
| Ronald J. Daniels Director | Jun 22, 2026 | Award | +3,990 | – | – | 20,981 |
| James C. Momtazee Director | Jun 22, 2026 | Award | +3,990 | – | – | 19,070 |
| Jennifer E. Cook Director | Jun 22, 2026 | Award | +3,990 | – | – | 10,579 |
| Andrea Ellis Director | Jun 22, 2026 | Award | +3,990 | – | – | 22,579 |
| Fred Hassan Director | Jun 22, 2026 | Award | +3,990 | – | – | 29,879 |
| Frank McCormick Director | Jun 22, 2026 | Award | +3,990 | – | – | 10,579 |
| Charles J. Homcy Director | Jun 22, 2026 | Award | +3,990 | – | – | 919,876 |
| Charles J. Homcy Director | Jun 20, 2026 | Tax withholding | −788 | $66.27 | $52.22K | 915,886 |
| Jennifer E. Cook Director | Jun 15, 2026 | Sale(10b5-1 plan) | −88,737 | $66.62 | $5.91M | 8,092 |
| Jennifer E. Cook Director | Jun 15, 2026 | Option exercise | +17,167 | $16.75 | $287.55K | 96,829 |
| Jennifer E. Cook Director | Jun 15, 2026 | Option exercise | +65,921 | $8.45 | $557.03K | 79,662 |
| Jennifer E. Cook Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,503 | $67.14 | $100.91K | 6,589 |
| Neil Kumar Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −7,148 | $67.20 | $480.35K | 4,331,299 |
| Neil Kumar Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −8,437 | $67.88 | $572.70K | 4,322,862 |
| Neil Kumar Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −8,437 | $67.88 | $572.70K | 520,102 |
| Neil Kumar Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −4,416 | $68.96 | $304.53K | 515,686 |
| Neil Kumar Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −4,415 | $68.96 | $304.46K | 4,318,447 |
| Neil Kumar Chief Executive Officer, Director | Jun 5, 2026 | Sale(10b5-1 plan) | −7,147 | $67.20 | $480.28K | 528,539 |
| Neil Kumar Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −450 | $68.27 | $30.72K | 4,338,447 |
| Neil Kumar Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −15,921 | $67.74 | $1.08M | 4,338,897 |
| Neil Kumar Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −1,429 | $66.72 | $95.34K | 4,354,818 |
| Neil Kumar Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,200 | $65.72 | $144.58K | 4,356,247 |
| Neil Kumar Chief Executive Officer, Director | Jun 4, 2026 | Sale(10b5-1 plan) | −450 | $68.27 | $30.72K | 535,686 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
16.62%
21M shares short
Days to cover
7.1
At 3M shares a day
Change since last report
+4.2%
From 20M shares
Short volume, 20 days
53.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BridgeBio Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 50,173 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kumar Haldea Family Irrevocable Tru/T/A Dtd 05/18/2019 Director, Officer | Aug 19, 2026 | 30,000 | $2.49M | Aug 19, 2026 | Conversion Management Incentive Units |
| Neil Kumar Director, Officer | Aug 18, 2026 | 34,980 | $2.79M | Aug 18, 2026 | Restricted Stock Units |
| Randal W. Scott Director | Aug 17, 2026 | 21,501 | $1.72M | Aug 17, 2026 | Exercise of Stock Options |
| Jennifer E. Cook Director | Jul 9, 2026 | 148,589 | $13.16M | Jul 9, 2026 | Stock Option Exercise |
| Andrea Ellis Director | Jul 9, 2026 | 17,167 | $1.44M | Jul 9, 2026 | Stock Option Exercise |
| Jennifer E. Cook Director | Jun 24, 2026 | 37,167 | $2.60M | Jun 24, 2026 | Stock Option Exercise |
| Randal W. Scott Director | Jun 24, 2026 | 2,196 | $150.71K | Jun 24, 2026 | Restricted Stock Units |
| Hannah Valantine Director | Jun 23, 2026 | 2,196 | $150.58K | Jun 23, 2026 | Restricted Stock |
| Jennifer E. Cook Director | Jun 23, 2026 | 2,196 | $150.58K | Jun 23, 2026 | Restricted Stock |
| Hannah Valantine Director | Jun 22, 2026 | 2,808 | $190.94K | Jun 22, 2026 | Stock Option Exercise |
| Jennifer E. Cook Director | Jun 15, 2026 | 90,240 | $6.01M | Jun 15, 2026 | Stock Option Exercise |
| Neil Kumar Director, Officer | May 21, 2026 | 26,103 | $1.78M | May 21, 2026 | Restricted Stock Units |
| Thomas Trimarchi Officer | May 18, 2026 | 13,651 | $888.42K | May 18, 2026 | Restricted Stock |
| Kumar Haldea Revocable Trust U/A Dtd 12/19/2018 Director, Officer | Apr 9, 2026 | 120,000 | $8.90M | Apr 9, 2026 | Conversion Management Incentive Units |
| Kumar Haldea Family Irrevocable Trust Director, Officer | Mar 13, 2026 | 140,000 | $9.52M | Mar 13, 2026 | Conversion Management Incentive Units |
See a number that looks wrong?